Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Microba Life Sciences Limited provides microbiome testing and analysis services for clinicians, consumers, and research customers in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. It offers pathology, therapeutics, and diagnostics services based on the human gut microbiome; Databank, for discovery of therapeutic leads, consumer health innovations, and diagnostic biomarkers; and data-driven therapeutics platform that develops novel monoclonal microbial cell therapies for inflammatory bowel disease, cancer immunotherapy, and autoimmune diseases. The company was incorporated in 2017 and is based in Brisbane, Australia.
Company Valuation
Based on key historical and expected multiples, the stock is slightly undervalued relative to its peers.
Target Price
The average target price of MAP.AX is 0.20 and suggests 160% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc